ASCO: Pembrolizumab Is Good Second-Line Tx in Urothelial CA

This article originally appeared here.
Share this content:
ASCO: Pembrolizumab Is Good Second-Line Tx in Urothelial CA
ASCO: Pembrolizumab Is Good Second-Line Tx in Urothelial CA

TUESDAY, Feb. 21, 2017 (HealthDay News) -- For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online Feb. 17 in the New England Journal of Medicine. The research was published to coincide with the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in Orlando, Fla.

Joaquim Bellmunt, M.D., Ph.D., from the Dana-Farber Cancer Institute in Boston, and colleagues randomized 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive pembrolizumab every three weeks or the investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine.

The researchers found that the median overall survival was 10.3 and 7.4 months in the pembrolizumab and chemotherapy groups, respectively (hazard ratio for death, 0.73); the corresponding median overall survival was 8.0 and 5.2 months for patients who had a tumor programmed death 1 (PD-L1) combined positive score of 10 percent or more (hazard ratio, 0.57). Progression-free survival did not differ significantly between the groups in the total population or among patients who had a tumor PD-L1 combined positive score of 10 percent or more. There were fewer treatment-related adverse events of any grade in the pembrolizumab group (60.9 versus 90.2 percent).

"Pembrolizumab was associated with significantly longer overall survival (by approximately three months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »